PURPOSE: To determine vitreous concentrations of triamcinolone acetonide(TA) following transseptal injection. METHODS: TA (40 mg/l ml) was administered at varying intervals prior to vitrectomy. Vitreous samples from 18 patients were obtained. TA concentrations were quantified using HPLC-MS. RESULTS: Vitreous levels of TA were detected in all samples (range 0.64-168.0 ng/ml). The interval from injection to sampling ranged from 0.5-20 days. Tmax was attained at 0.5 days. TA concentrations were negatively correlated with scleral thickness (P = 0.0184) and depot location (P = 0.0230) but not with PVD status (P = 0.9633). CONCLUSION: Significant vitreous concentrations of TA are achieved after a single transseptal injection. Scleral thickness, depot location and time influence vitreous TA levels.
PURPOSE: To determine vitreous concentrations of triamcinolone acetonide(TA) following transseptal injection. METHODS:TA (40 mg/l ml) was administered at varying intervals prior to vitrectomy. Vitreous samples from 18 patients were obtained. TA concentrations were quantified using HPLC-MS. RESULTS: Vitreous levels of TA were detected in all samples (range 0.64-168.0 ng/ml). The interval from injection to sampling ranged from 0.5-20 days. Tmax was attained at 0.5 days. TA concentrations were negatively correlated with scleral thickness (P = 0.0184) and depot location (P = 0.0230) but not with PVD status (P = 0.9633). CONCLUSION: Significant vitreous concentrations of TA are achieved after a single transseptal injection. Scleral thickness, depot location and time influence vitreous TA levels.